Thermo Fisher Scientific (TMO): Sector Reads Convey Confidence in End-Market Growth - Leerink

November 18, 2016 6:27 AM EST
Get Alerts TMO Hot Sheet
Price: $145.41 +1.64%

Rating Summary:
    23 Buy, 2 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 21 | Down: 36 | New: 11
Trade TMO Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Leerink Partners analyst, Puneet Souda, reiterated his Outperform rating on shares of Thermo Fisher Scientific (NYSE: TMO) after two recent events gave the analyst confidence in TMO's ability to drive ~5% organic sales and double digit EPS growth:


1)Agilent's fourth quarter report delivered 16% biopharma growth, suggesting that as of October 31st (A's off-cycle 4Q16 close), biopharma end-market growth in the sector remains not only healthy but also accelerated at a time when the Street was getting cautious on it

2) meeting with TMO's Senior Director of Investor Relations, Rafael Tajeda, to discuss the overall business which gave the analyst confidence in TMO's ability to deliver, despite any uncertainty caused by the U.S. election and the pending NIH funding appropriations

No change to the price target of $175.

For an analyst ratings summary and ratings history on Thermo Fisher Scientific click here. For more ratings news on Thermo Fisher Scientific click here.

Shares of Thermo Fisher Scientific closed at $148.88 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change

Add Your Comment